Skip to main content

Pterygium

6
Pipeline Programs
7
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
2
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 6 programs with unclassified modality

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Arrowhead Pharmaceuticals
1 program
1
BevacizumabPhase 4Monoclonal Antibody1 trial
Active Trials
NCT01736449Completed31Est. Apr 2012
International Stem Cell
1 program
1
Cultivated conjunctival transplantationPhase 31 trial
Active Trials
NCT00346450Completed80Est. Dec 2003
Baxter
BaxterCosta Rica - Cartago
1 program
1
Pterygium excision and conjunctival autograftPhase 3
Allgenesis Biotherapeutics
1 program
1
0.1% AG-86893 Eye DropsPhase 2
BioTherapeutics Inc
BioTherapeutics IncVA - Blacksburg
1 program
1
0.1% AG-86893 Eye DropsPhase 21 trial
Active Trials
NCT03533244Completed64Est. Oct 2019
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
cyclosporine ophthalmic emulsion 0.05%Phase 21 trial
Active Trials
NCT01109056Completed115Est. Jun 2011
Baxter International
1 program
Pterygium excision and conjunctival autograftPHASE_31 trial
Active Trials
NCT00326560Unknown40Est. Sep 2007

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Arrowhead PharmaceuticalsBevacizumab
Baxter InternationalPterygium excision and conjunctival autograft
International Stem CellCultivated conjunctival transplantation
BioTherapeutics Inc0.1% AG-86893 Eye Drops
AbbViecyclosporine ophthalmic emulsion 0.05%

Clinical Trials (5)

Total enrollment: 330 patients across 5 trials

NCT01736449Arrowhead PharmaceuticalsBevacizumab

Role of Sub-Conjunctival Bevacizumab in Post Pterygium Excision Management

Start: Apr 2011Est. completion: Apr 201231 patients
Phase 4Completed
NCT00326560Baxter InternationalPterygium excision and conjunctival autograft

Comparison of Glue With Sutures for Pterygium Surgery

Start: May 2006Est. completion: Sep 200740 patients
Phase 3Unknown
NCT00346450International Stem CellCultivated conjunctival transplantation

Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Transplantation

Start: Oct 2001Est. completion: Dec 200380 patients
Phase 3Completed
NCT03533244BioTherapeutics Inc0.1% AG-86893 Eye Drops

A Study of the Response to AG-86893 in Patients With Pterygium Hyperemia

Start: Oct 2018Est. completion: Oct 201964 patients
Phase 2Completed
NCT01109056AbbViecyclosporine ophthalmic emulsion 0.05%

Safety and Efficacy of Cyclosporine Ophthalmic Emulsion in Patients With Primary Pterygium

Start: Jun 2010Est. completion: Jun 2011115 patients
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.